lobbying_activities: 1808105

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1808105	8043822d-89e5-40ae-a031-c2086577e96e	Q1	RED+BLUE STRATEGIES	400693064	COHERUS BIOSCIENCES	2016	first_quarter	PHA	FDA's March 31, 2016 Biosimilars Labeling Guidance. Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have on drug cost and access.	HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2016-04-14T16:42:24.337000-04:00